Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
**Phone** 503-947-5220 | **Fax** 503-947-1119

# Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, February 1st, 2024
1:05 PM - 4:45 PM
Via Zoom webinar

## MEETING MINUTES

---

**NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333**

**Members Present:** Stacy Ramirez, PharmD; Patrick DeMartino, MD; Bridget Bradley, PharmD; Douglas Carr, MD; Tim Langford, PharmD; Eriko Onishi, MD; Eddie Saito, PharmD; **Ad-Hoc: Erika Finanger, MD**

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Kendal Pucik, PharmD Candidate 2024; Brandon Wells; Trevor Douglass, DC; Jennifer Bowen; Kyle Hamilton

**Audience: Craig Sexton*, GSK; Nirmal Ghuman*, J&J; Tao Wang*, Climate Works; Brian Denger *, Parent Project Muscular Dystrophy; Adam Gold*, NS Pharma; Armen Khachatourian*, Sarepta**; Mark Kantor, AllCare Health; Robin Wells, NS Pharma; Suzanne Morgan, NS Pharma; Melissa Abbott, Eisai; Lori McDermott, Viking HCS; Mike Donabedian, Sarepta; Jim Cromwell, Sarepta; Shirley Kim, Sarepta; Leslie Zanetti, Sarepta; Mindy Cameron; Chris VanWynen, Sarepta; Leif Bruce, Novo Nordisk; Gary Parenteau, Dexcom; Brielle Dozier, Artia Solutions; Tracy Copeland, Sarepta; Brandie Ferger, Advanced Health; Yesina Camacho, PharmD Candidate w/ Umpqua Health; Saghi Maleki, Takeda; Lisa Pulver, J&J; Chris Ferrin, IHN; Leanne Yantis, AllCare; Robert Pearce, Karuna; Uche Mordi, Karuna; Cheryl Bondy, Sobi; Emily Cooper; Alexandria Jarvais, Sobi; Matt Worthy, OHSU; Tiina Andrews, UHA; Mark England, Mercer; Daria Meleshkina, Moda/EOCCO; Samyukta Vendrachi; Long Nguyen; Philip Santa Maria; Bryan Armstrong, CareOregon; Melissa Bailey Hall; Susan Lakey Kevo; Melissa Snider, Gilead; Michele Sabados, Alkermes; Paul Thompson, Alkermes; Shauna Wick, Trillium; Jeff White, Sumitomo; Amy Aikins, Little Hercules Foundation; Richie Kahn, Canary Advisors; Kate Ogden

**(*) Provided verbal testimony**

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
**Phone** 503-947-5220 | **Fax** 503-947-1119

## I. CALL TO ORDER

**A.** Roll Call & Introductions
- Called to order at approx. 1:05 p.m., introductions by Committee and staff

**B.** Conflict of Interest Declaration – no new conflicts of interest were declared

**C.** Election of Chair and Vice Chair
**Dr. Ramirez volunteered to serve as Chair and Dr. DeMartino as Vice-Chair**
**ACTION: Motion to approve, 2nd, all in favor**

**D.** Approval of Agenda and December 2023 Minutes presented by Mr. Citron
**ACTION: Motion to approve, 2nd, all in favor with one abstention**

**E.** Department Update provided by Andrew Gibler, PharmD

**F.** Legislative Update provided by Trevor Douglass, DC, MPH

## II. CONSENT AGENDA TOPICS

**A.** **Preferred Drug List (PDL): Insulin Literature Scan -** Deferred to April P&T Meeting

**B.** **P&T Evidence Methods**

**C.** **P&T Operating Procedures**

**D.** **Oncology Prior Authorization (PA) Updates**
**Recommendation:**
- Add: Akeega ™ (abiraterone acetate/niraparib tosylate); Truqap™ (capivasertib); Xalkori® (crizotinib); Fruzaqla™ (fruquintinib); Hepzato Kit™ (Melphalan HCl/hepatic delivery kit (HDS)); Ogsiveo™ (nirogacestat hydrobromide); Augtyro™ (repotrectinib); and Loqtorzi™ (toripalimab-tpzi) to Table 1 in the Oncology Agents PA criteria

**E.** **Orphan Drug Policy Updates**
**Recommendation:**
- Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Reblozyl ® (luspatercept-aamt); and Bylvay™ (odevixibat) based on FDA-approved label
**ACTION: Motion to approve, 2nd, all in favor**

## III. DUR ACTIVITIES

**A.** **Quarterly Utilization Report:** Roger Citron, RPh

**B.** **ProDUR Report**: Lan Starkweather, PharmD

**C.** **RetroDUR Report**: Dave Engen, PharmD

**D.** **Oregon State Drug Review**: Kathy Sentena, PharmD
1. **An Update in Weight Loss Therapies-Including FDA Approved GLP-1 Receptor Agonists**
2. **Prevention of Respiratory Syncytial Virus (RSV) Infection: New Products and Recommendations**

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
**Phone** 503-947-5220 | **Fax** 503-947-1119

## IV. DUR OLD BUSINESS

**A. Spravato® (esketamine) PA Update:** Sarah Servid, PharmD
**Recommendation:**
- Update the safety edit for esketamine to include outpatient initiation for people with suicidal ideation who have optimized first-line alternative treatments for depression
**Public Comment:** Nirmal Ghuman, J&J
**ACTION:** The Committee recommended ensuring the approved doses match the FDA approved labeling for each indication
**Motion to approve, 2nd, all in favor**

## V. DUR NEW BUSINESS

**A. Antipsychotics in Children Policy Evaluation:** Sarah Servid, PharmD
**Recommendation:**
- Update the Antipsychotics in Children safety edit to include assessment of rapid weight gain for members without glucose monitoring, consider allowing longer initial therapy before PA is required, and apply the policy to members who are three to six years of age
**ACTION:** The Committee recommended allowing up to 60 days initial therapy before PA is required and to explore options to notify providers about the policy before members have a denied claim
**Motion to approve, 2nd, all in favor**

**B. Melatonin Policy Evaluation**:
Kendal Pucik, PharmD Candidate 2024 and Megan Herink, PharmD
**Recommendations:**
- No policy changes recommended based on the policy evaluation
**ACTION: Motion to approve, 2nd, all in favor**

## VI. PREFERRED DRUG LIST (PDL) NEW BUSINESS

**A. Lantidra™ (donislecel) New Drug Evaluation:** Kathy Sentena, PharmD
**Recommendations:**
- Implement the proposed PA for donislecel to ensure that it is used in patients in which the benefits outweigh the risks of transplant
**ACTION: Motion to approve, 2nd, all in favor**

**B. Maintenance Inhalers for Asthma/COPD:** Deanna Moretz, PharmD

**Recommendations:**

- Designate at least one long-acting muscarinic antagonist-long-acting beta agonist (LAMA-LABA) combination agent preferred on the PMPDP PDL changes recommended based on the review of recently published evidence
- Remove PA requirements for preferred LAMA-LABA and preferred long-acting muscarinic antagonistlong-acting beta agonist-inhaled corticosteroid (LAMA-LABA-ICS) combination products
- Maintain Airsupra™ (albuterol-budesonide) and Symbicort® Aerosphere™ (budesonide 160 mcg-formoterol 4.8 mcg) as non-preferred inhalers on the PMPDP
- Evaluate costs in executive session

**Public Comment:** Craig Sexton, GSK

**ACTION: Motion to approve, 2nd, all in favor**

**C. Duchenne Muscular Dystrophy DERP Report and NDE:** Sarah Servid, PharmD

**Recommendations:**

- Implement the proposed PA criteria for delandistrogene moxeparvovec (Elevidys™) to limit use to the FDA-approved indication
- Based on the review of recently published evidence no PDL changes to the preferred corticosteroids were recommended
- Update the DMD PA criteria to apply to all non-preferred corticosteroids for DMD
- Evaluate costs in executive session

**Public Comment:** Tao Wang, parent; Brian Denger, Parent Project Muscular Dystrophy; Adam Gold, NS Pharma; Armen Khachatourian, Sarepta

**ACTION:** The Committee modified the proposed PA criteria to require prescribing by a neuromuscular specialist and to require documentation of informed consent for members with deletions of exons 1-17 or 59-71

**Motion to approve, 2nd, all in favor with one abstention**

**D. Antivirals for SARS-CoV2 Class Review:** Deferred to April P&T Meeting

## VII. EXECUTIVE SESSION

**Members Present:** Stacy Ramirez, PharmD; Patrick DeMartino, MD; Bridget Bradley, PharmD; Douglas Carr, MD; Eriko Onishi, MD; Eddie Saito, PharmD; **Ad-Hoc: Erika Finanger, MD**

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
**Phone** 503-947-5220 | **Fax** 503-947-1119

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Kendal Pucik, PharmD Candidate 2024; Brandon Wells; Kyle Hamilton

## VIII. RECONVENE for PUBLIC RECOMMENDATIONS

**A. Maintenance Inhalers for Asthma/COPD**
**Recommendation:** Make Arnuity™ Ellipta® (fluticasone furoate) preferred
**ACTION: Motion to approve, 2nd, all in favor**

**B. Duchenne Muscular Dystrophy (DMD)**
**Recommendations:** Designate all targeted DMD therapies as non-preferred and make Emflaza® (deflazacort) and Agamree® (vamorolone) non-preferred
**ACTION: Motion to approve, 2nd, all in favor with one abstention**

## IX. ADJOURN